Logo

Genomatica to Develop In Silico Model for Dow Chemical

Sep 18, 2002

NEW YORK, Sept. 18 - Genomatica is developing an in silico model for Dow Chemical to predict the effect of genetic changes on microbial metabolism and bioprocessing, the companies announced today.

 

Genomatica, based in San Diego, will use its SimPheny platform to develop the modeling for Dow, according to the company.

 

Financial details of the agreement were not disclosed, though the company said Dow would provide research support and milestone payments.

Breaking News
The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.